

29 October 2012

ASX Limited
 Quotations
 20 Bridge Street
 Sydney NSW 2000
quotations@asx.com.au

DISPATCH OF OPTIONS ENTITLEMENTS OFFER HOLDING STATEMENTS

Cellmid Limited wishes to provide information in relation to the options issued in connection with the Company's Options Entitlements Offer that closed recently:

- Options were issued at \$0.002 per option with an exercise price of \$0.034 and with a term of 4 years;
- 272,542,770 options were issued in respect of acceptances on Friday, 26 October 2012;
- 15,000,000 options were issued on Monday, 17 September 2012 in respect of consulting fees;
- 3,000,000 options were issued on Friday, 26 October 2012 in respect of underwriting fees;
- Holding statements in relation to the shares issued have been dispatched today;
- The total capital of the Company following the issue is 545,085,540 shares, and 290,542,770 listed options;
- The Distribution of Holders is as per the following schedule:

Category	No of holders	No of Units	% of Issued Options
1-1,000	3	2,150	0.00%
1,001-5,000	21	88,500	0.03%
5,001-10,000	36	293,553	0.10%
10,000-100,000	196	8,474,345	2.92%
100,001 and over	144	281,684,222	96.95%
	400	290,542,770	100.00%

- The 20 largest holdings of the options issued in relation to the Company's Options Entitlement Offer and the percentages held are as follows:

Name	Options	% of total
Baru Resources Limited	50,000,000	17.21%
Black Cygnet Pty Ltd	35,929,230	12.37%
Mosche Schmuelian	25,000,000	8.60%
Peter Andrew Proksa	13,000,000	4.47%
Structure Investments Pty Ltd <Rogers Family Trust A/C>	12,000,000	4.13%
Seistend Pty Ltd <Dw King Super Fund A/C>	11,250,000	3.87%
Hera Investments Pty Ltd	10,606,061	3.65%
Mr James Patrick Tuite & Mrs Wendy Tuite <Tuite Super 1 A/C>	10,323,231	3.55%
Mr Gregory Glenn Worth <Worth S/F A/C>	8,000,000	2.75%
Mr Trevor Gottlieb	5,000,000	1.72%
Lims Design Services Pty Ltd <Lims Drafting S/F A/C>	3,500,000	1.20%
Mr Darin Anjoul & Mrs Tania Anjoul	3,200,000	1.10%
Talrind Pty Ltd <Worth D/T A/C>	3,000,000	1.03%
Fagan Superannuation A/C	3,000,000	1.03%
RM Capital Pty Ltd Level 2, 6 Kings Park Road	3,000,000	1.03%
Rogers SF Management Pty Ltd <Rogers Super Fund A/C>	3,000,000	1.03%
Mr Trevor Gottlieb	2,961,500	1.02%
Mr Darin Anjoul <The Tan Group Super A/C>	2,800,000	0.96%
Mr Paul Ruggiero & Mrs Lorissa Ruggiero <L & P Ruggiero S/F A/C>	2,675,000	0.92%
Mr Paul Ruggiero & Mrs Lorissa Ruggiero	2,625,000	0.90%
Total Top 20 Option Holders	210,870,022	72.58%
Total Options Issued	290,542,770	100.00%

End

Contact:

Maria Halasz, CEO

T +612 9299 0311

Cellmid Limited (ASX: CDY)

Cellmid is an Australian biotechnology company developing innovative novel therapies and diagnostic tests for inflammatory diseases, heart attack and cancer. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to midkine and midkine antagonists globally. The Company's most advanced clinical development program is for the treatment of acute myocardial infarction (AMI) utilising the midkine protein. Cellmid is also developing anti-midkine antibodies for the treatment of inflammatory and autoimmune disorders. In addition, Cellmid is commercialising midkine as a biomarker for cancer diagnosis. Elevated midkine concentration in the blood and other body fluids is strongly indicative of cancer. Cellmid's first product, the MK-ELISA, is a blood test that sensitively and accurately measures serum midkine levels.